The aim of this study was to investigate inflammatory/fibrotic biomarkers, including biochemical analytes, acute phase proteins and KL-6 to determine whether single mediator or panels of mediators could be useful to stratify patients into three distinct domains: sarcoidosis, IPF and cHP. This evidence concerns the gene MUC1 and idiopathic pulmonary fibrosis.